Endpoints News

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies At least seven members of Congress since 2023 have bought and sold stocks of life science companies that would gain from legislation to ban several key Chinese biotech suppliers and contractors, according to financial disclosures. The Biosecure Act, which advanced in the House last week, would force...

Senior Biopharma Correspondent Andrew Dunn sat down (virtually) with biotech's Renaissance man, Siddhartha Mukherjee, in the latest Endpoints Slack Interview. They talked about AI, Mukherjee's slew of ambitious biotech startups, and how he got into writing epic, Pulitzer-winning tomes on medicine and science.

The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him in many directions, including running a research lab at Columbia University, co-founding a growing list of biotech startups, and writing books on s...

Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes.

Novo clears Phase 3 hemophilia A trial, plans to submit application by year's end Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes. Following the topline FRONTIER 2 data disclosure via a press release, the Danish drugmaker's shares $NVO...

Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday.

Across two clinical trials, gene therapy restores hearing in children deaf since birth: #ASGCT24 BALTIMORE — Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday. The children who recovered their hearing are also showing improvements in their ability to speak. Some are saying the words “mama.....

For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the market felt unimpeachable, with AbbVie’s Humira retaining 96% of the share by February. That changed when Humira came off the formulary of CVS Health’s pharmacy benefit manager Caremark.

Inside CVS Caremark’s move that broke Humira’s hold on the market (This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the market felt unimpeachable, with AbbVie's Humira retaining 96% of the

A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed.

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed. The patient received fordadistrogene movaparvovec in early 2023 as part of Pfizer’s DAYLIGHT study enrolling patients 2 and 3 years old. As a result o...

The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday, some of which would affect how the next round of drug prices is negotiated under the Inflation Reduction Act. On Monday, industry groups PhRMA and BIO raised new concerns about the guidance.

Industry groups critique new guidance for Medicare drug price negotiations in 2027 The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday, some of which would affect how the next round of drug prices is negotiated under the Inflation Reduction Act. On Monday, industry groups PhRMA and BIO raised new concerns about t...

AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week.

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a site that employs more than 2,000 already, the new building will house more than 300 employees in onco...

Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on business in first-quarter earnings calls.

Pharma companies soften tone on full IRA impact Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on business in first-quarter earnings calls. All three companies voiced early opposition to the IRA, liken...

Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health Organization-led global pandemic preparedness agreement that’s nearing completion.

Sanders presses pharma leaders to change stance on Pandemic Accord proposals Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health Organization-led global pandemic preparedness agreement that's nearing completion. On Thursday, Sanders wrote to the International Federation of Pharmaceutical Manufacturers and....

GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners.

GSK accuses Pfizer and BioNTech of mRNA patent infringement GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners. In a lawsuit filed in federal court in Delaware Thursday, the UK pharma claimed Pfizer and BioNTech benefited from mRNA research conducted more than a decad...

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets.

Roche unruffled by China bill as it looks to grow roots in the region Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets. “We’ve really worked on diversifying our supply chain and this is helping us now, so that we have multiple partners to work with acros...